Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2Wilms Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Peritoneal Cavity Cancer 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1High Grade Serous Ovarian 1Gliosarcoma 1Gastrointestinal Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma 1Astrocytoma 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Cytoreduction Surgical Procedures × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡